1130: Identification of Novel Molecular Signatures Associated with the Therapeutic Response to DMARDs and TNFi Therapies in Rheumatoid Arthritis Patients Through High Throughput Proteomics

Carlos Pérez-Sánchez¹, Laura Muñoz-Barrera¹, Tomás Cerdó², Ismael Sánchez-Pareja², Jerusalem Calvo-Gutierrez², Rafaela Ortega-Castro¹, Montserrat Romero-Gomez², María Ángeles Aguirre-Zamorano³, María Carmen Ábalos-Aguilera⁴, Nuria Barbarroja¹, José Perez-Venegas⁵, Mª Dolores Ruiz-Montesinos⁵, Carmen Dominguez⁵, Carlos Rodriguez-Escalera⁶, Carmen Romero-Barco⁶, Antonio Fernandez-Nebro⁷, Natalia Mena Vazquez⁷, Jose Luis Marenco⁸, Julia Uceda Montañez⁸, Charo Santos⁹, Eduardo Collantes¹, Alejandro Escudero-Contreras² and Chary Lopez-Pedrera¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁴Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁵Virgen Macarena University Hospital, Sevilla, Spain, ⁶Virgen de la Victoria Hospital, Málaga, Spain, ⁷Regional University Hospital of Málaga, Málaga, Spain, ⁸Virgen de Valme University Hospital, Sevilla, Spain, ⁹Virgen de Valme University Hospital, Málaga, Spain

Background/Purpose: The clinical outcome of conventional disease-modifying antirheumatic drugs (DMARDs) and TNF inhibitors (TNFi) is still unpredictable in rheumatoid arthritis (RA) patients. Thus, innovative analyses combining high-throughput technologies and thorough clinical assessments are needed. The aim of this study was to evaluate the systemic inflammatory proteome of RA patients to identify useful biomarkers associated with distinctive clinical outcomes.

Methods: Serum samples from 140 subjects, including 40 healthy donors (HC) and 100 RA patients with high activity disease (mean DAS28=4.7), were profiled with the innovative proteomic methodology "proximity extension assay" (Olink) which analyses one panel of 92 pro-inflammatory proteins. Samples from RA active patients included 40 from newly-diagnosed RA patients before taking conventional DMARDs and 100 from biologics-naïve patients (mean disease duration=10 years) before receiving TNFi drugs. Clinical outcomes were evaluated following EULAR criteria after 6 months of treatment and patients were classified as responders or non-responders to the different drugs. Unsupervised hierarchical clustering methodologies were applied to identify subgroups of patients based on the proteomic profiles. Gene ontology enrichment was used to interrogate the biological meaning of the distinctive molecular signatures identified.

Results: The inflammatory proteome analysis identified 33 proteins differentially expressed and upregulated in RA patients compared with HC including several chemokines (CCL-11, -19, -20, -23, -28; CXCL-10, -11, -9; MCP-1, -3), interleukins (IL-6, -8, -18, -10, -17c), and other relevant proinflammatory mediators (VEGFA, CD40, MMP-1, CSF-1, OPG, FGF23) among others (FDR< 0.05). Most of these molecules were associated with disease activity (DAS28) and the autoimmunity profile (Rheumatoid factor and ACPAs antibodies) of RA patients. The unsupervised clustering analysis using the proteomic profile of RA patients before TNFi identified two subgroups of patients. Cluster 1 (C1) was characterised by patients with higher levels of several pro-inflammatory mediators compared with Cluster 2 (C2), where a signature of 16 chemokines was significantly enriched (CCL-3, -4, -10, -11, -20, -23; CX3CL1; CXCL-1, -10, -11, -5, -6, -9; MCP-1, -3, -4). Clinically, 25% of the non-responders' patients was included in C2, while 75% was located in C1, suggesting that a prominent circulating chemotaxis profile prior to therapy is associated with a poor clinical outcome. These data were similarly observed in patients before receiving DMARDs, where a signature of upregulated chemokines and pro-inflammatory mediators characterized a cluster with a high % of non-responder patients.

Conclusion: A pro-inflammatory signature, where chemokines are predominantly up-regulated in the serum of RA patients before therapy, is associated with a poor clinical outcome. This newly identified signature, which deserves a more in-depth analysis, might be clinically useful in guiding precision medicine and novel therapeutic approaches.

Supported by ISCIII (PI21/005991 and RICOR-RD21/0002/0033) co-financed by FEDER and CTEICU, Junta de Andalucía (P20_01367).

Disclosures: C. Pérez-Sánchez, None; L. Muñoz-Barrera, None; T. Cerdó, None; I. Sánchez-Pareja, None; J. Calvo-Gutierrez, None; R. Ortega-Castro, None; M. Romero-Gomez, None; M. Aguirre-Zamorano, None; M. Ábalos-Aguilera, None; N. Barbarroja, None; J. Perez-Venegas, None; M. Ruiz-Montesinos, None; C. Dominguez, None; C. Rodriguez-Escalera, None; C. Romero-Barco, None; A. Fernandez-Nebro, None; N. Mena Vazquez, None; J. Marenco, None; J. Uceda Montañez, None; C. Santos, None; E. Collantes, None; A. Escudero-Contreras, None; C. Lopez-Pedrera, None.